Daiichi Sankyo
Mark Hanke currently serves as Principal Medical Science Liaison at Daiichi Sankyo US, a role commenced in July 2023. Prior to this position, Mark held various senior roles in medical science liaison, including Senior Medical Science Liaison II - Oncology at Alkermes from January 2019 to July 2023, and Senior Medical Science Liaison - Oncology at Mallinckrodt Pharmaceuticals from April 2015 to December 2018. Earlier experience includes serving as a Post Doctoral Researcher at Fred Hutchinson Cancer Research Center in the Clinical Research Division focusing on ImmunoOncology and the Tumor Microenvironment, and as a Post Doctoral Research Associate at the University of Nebraska Medical Center in the Department of Pathology & Microbiology, working on innate immunity. Mark holds a Ph.D. in Biomedical Science with a focus on Immunology from The Ohio State University and a B.A. in Biochemistry and Molecular Biology from The College of Wooster.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.